Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Webcasts|May 18, 2020
Bulletproof your Supply Chain: Hope for the Best, Prepare for the Worst
Author(s)Thermo Fisher Scientific
Learn from the experts on how to best combine supply-chain management and logistics expertise to build a nimble and efficient operation that can help to mitigate risks such as those brought on by the COVID-19 pandemic. Live: Monday, May 18, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing May 18, 2021 Register free
Register free:
Event Overview:
Incorporating a well-thought out contingency plan is critical when developing a clinical and commercial supply chain. During global uncertainty, such as the COVID-19 pandemic, being properly prepared can help a pharmaceutical company navigate through the increased complexities to deliver its drug to the right place at the right time. Learn from the experts how to best combine supply-chain management and logistics expertise to build a nimble and efficient operation.
Key Learning Objectives:
- Why it is critical to manage, optimize, and streamline a supply chain
- How to incorporate flexibility in planning to overcome potential challenges
- The value of having a contingency plan, even if it is never needed
- How to use a risk-based approach to determine where a contingency plan is needed
Speakers: Michelle Friedman, Program Director, Clinical Supply Optimization Services, Thermo Fisher Scientific
Jason Mieding, Global Leader, Total Transportation Management, Thermo Fisher Scientific
Time and Date: Monday, May 18, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after final airing May 18, 2021
Sponsor: Thermo Fisher Scientific
Register free:
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5